Biogen Company Research Report

Company Overview

• Name: Biogen

• Mission: No information is available

• Founded: No information is available

• Founders: No information is available

• Key People:

• Christopher A. Viehbacher - President and Chief Executive Officer

• Susan H. Alexander - Chief Legal Officer

• Ginger Gregory, Ph.D. - Chief Human Resources Officer

• Jane Grogan, Ph.D. - Head of Research

• Rachid Izzar - Head of Global Product Strategy & Commercialization

• Adam Keeney - Head of Corporate Development

• Michael McDonnell - Chief Financial Officer

• Nicole Murphy - Head of Pharmaceutical Operations and Technology

• Priya Singhal, M.D., M.P.H. - Head of Development and Interim Chief Medical Officer

• Alisha Alaimo - President, Head of North America

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Biogen is known for its commitment to discovering innovative treatments in areas with significant unmet needs, such as Alzheimer's Disease, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and various other neurological and immunological conditions.

Products

Therapies and Medicines

1. Aduhelm® (aducanumab-avwa)

• Description: A treatment for Alzheimer's Disease; however, commercialization and development have been discontinued.

• Features: Monoclonal antibody designed to target amyloid-beta in Alzheimer’s patients. Discontinued in favor of LEQEMBI®.

2. Avonex® (interferon beta-1a)

• Description: Neuroscience therapy for multiple sclerosis.

• Features: Reduces the frequency of MS relapses.

3. Fampyra® (prolonged-release fampridine tablets)

• Description: Neuroscience therapy designed to improve walking in people with MS.

• Features: Potassium channel blocker.

4. LEQEMBI® (lecanemab-irmb)

• Description: Partnership product with Eisai for treating Alzheimer's disease.

• Features: Monoclonal antibody targeting amyloid-beta.

5. Ocrevus® (Ocrelizumab)

• Description: Neuroscience therapy for Multiple Sclerosis, in collaboration with Genentech.

• Features: Designed to selectively target CD20-positive B cells.

6. Plegridy® (peginterferon beta-1A)

• Description: Drug for multiple sclerosis.

• Features: Modified to extend half-life, requiring less frequent dosing.

7. Spinraza® (nusinersen)

• Description: Antisense oligonucleotide for the treatment of spinal muscular atrophy.

• Features: Targets and alters splicing of SMN2 gene.

8. Tysabri® (natalizumab)

• Description: Therapy for multiple sclerosis.

• Features: Designed to suppress inflammatory potential of immune cells by inhibition of α4-integrin.

Recent Developments

• New Collaborations:

• October 29, 2024: Biogen and Neomorph announced a multi-target research collaboration to discover and develop molecular glue degraders for Alzheimer's, rare, and immunological diseases.

• Appointments and Retirements:

• October 29, 2024: Biogen appointed Daniel Quirk, MD, as Chief Medical Officer.

• October 28, 2024: Announcement of Michael McDonnell, Executive Vice President, and Chief Financial Officer’s retirement in February 2025.

• Research and Trials:

• October 26, 2024: Presentation of positive results from Phase 2 IGNAZ study of Felzartamab in IgA Nephropathy at ASN Kidney Week 2024.

• Pipeline Updates:

• Neuroscience Focus: Ongoing research and clinical trials in areas such as Alzheimer’s Disease and Dementia, Amyotrophic Lateral Sclerosis (ALS), and more, with promising candidates like Lecanemab and Tofersen pushing through late-phase development.

Conclusion

Biogen continues to pioneer in the biotechnology sector with a strong emphasis on neurological and immunological disorders. The company is expanding its research collaborations and strengthening its pipeline with innovative treatments, maintaining its role as a leader in the biopharmaceutical industry.